288 results on '"Bouckenooghe, Alain"'
Search Results
2. Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand
3. Impact of Dengue Vaccination on Serological Diagnosis : Insights From Phase III Dengue Vaccine Efficacy Trials
4. Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV–Primed Children in the Philippines
5. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population : Assessment of Vaccine Viremia and Virus Shedding
6. Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization
7. Three Decades of Dengue Surveillance in Five Highly Endemic South East Asian Countries : A Descriptive Review
8. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children
9. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction
10. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study
11. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
12. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan
13. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children
14. A Review of Rotavirus Infection in and Vaccination of Human Immunodeficiency Virus—Infected Children
15. Efficacy of the Human Rotavirus Vaccine RIX4414 in Malnourished Children
16. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
17. The Epidemiology of HIV and AIDS Among Central American, South American, and Caribbean Immigrants to Houston, Texas
18. Stability of Zika Virus Antibodies in Specimens from a Retrospective Serological Study
19. Spatiotemporal Heterogeneity of Zika Virus Transmission in Indonesia: Serosurveillance Data from a Pediatric Population
20. IL8 - Clinical development update: 1st dengue vaccine candidate
21. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
22. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study
23. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
24. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore
25. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis
26. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus
27. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children
28. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y:: Phase II randomized controlled trial in Singapore
29. Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries.
30. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months:: Randomized, controlled phase 3 immunogenicity and safety trial
31. Corrigendum to: Dengue Endemicity, Force of Infection and Variation in Transmission Intensity From 13 Endemic Countries
32. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus
33. Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries
34. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
35. Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization
36. Spatiotemporal Heterogeneity of Zika Virus Transmission in Indonesia: Sero surveillance Data from a Pediatric Population.
37. Achieving regulatory success in Phases IIIb and IV: well-planned studies designed to pinpoint additional data are increasingly important as a result of the EU's emphasis on added therapeutic value
38. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial
39. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series.
40. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response
41. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
42. Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand
43. OR23 HLA class II genes correlate with protective neutralizing antibody titers in a dengue vaccine efficacy trial
44. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine
45. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series.
46. Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand.
47. Serological Evidence of Japanese Encephalitis Virus Circulation in Asian Children From Dengue-Endemic Countries
48. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
49. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia
50. Correction: Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.